Clinical Trial

A Single-arm, Multicenter, Phase II Clinical Study of Camrelizumab Combined With Famitinib in Adjuvant Therapy After Radical Resection of Cervical Cancer

Name: A Single-arm, Multicenter, Phase II Clinical Study of Camrelizumab Combined With Famitinib in Adjuvant Therapy After Radical Resection of Cervical Cancer — clinical trial record (NCT07466901)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting

View on ClinicalTrials.gov →

Summary

This study is a single-arm, open-label, multicenter, exploratory clinical trial aimed at observing and evaluating the efficacy and safety of camrelizumab combined with famitinib in the adjuvant treatment of cervical cancer patients after surgery.

Trial Details

NCT Number	NCT07466901
Lead Sponsor	Jin LI
Conditions	Cervical Cancer, Radical Surgery, Adjuvant Therapy
Enrollment	30 participants
Start Date	2026-04-01
Primary Completion	2030-04-01 (estimated)
Study Completion	2030-08-31 (estimated)
Updated on ClinicalTrials.gov	2026-03-12